[go: up one dir, main page]

PT3394046T - Reguladores de cftr e seus métodos de uso - Google Patents

Reguladores de cftr e seus métodos de uso

Info

Publication number
PT3394046T
PT3394046T PT168801595T PT16880159T PT3394046T PT 3394046 T PT3394046 T PT 3394046T PT 168801595 T PT168801595 T PT 168801595T PT 16880159 T PT16880159 T PT 16880159T PT 3394046 T PT3394046 T PT 3394046T
Authority
PT
Portugal
Prior art keywords
methods
cftr
regulators
cftr regulators
Prior art date
Application number
PT168801595T
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT3394046T publication Critical patent/PT3394046T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT168801595T 2015-12-24 2016-12-23 Reguladores de cftr e seus métodos de uso PT3394046T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387579P 2015-12-24 2015-12-24
US201662376808P 2016-08-18 2016-08-18

Publications (1)

Publication Number Publication Date
PT3394046T true PT3394046T (pt) 2022-04-05

Family

ID=59091221

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168801595T PT3394046T (pt) 2015-12-24 2016-12-23 Reguladores de cftr e seus métodos de uso

Country Status (19)

Country Link
US (2) US11084795B2 (pt)
EP (2) EP3394046B1 (pt)
JP (2) JP6938509B2 (pt)
KR (1) KR102743295B1 (pt)
CN (1) CN108699040B (pt)
AU (1) AU2016377785B2 (pt)
BR (1) BR112018012934B1 (pt)
CA (1) CA3009534A1 (pt)
CL (1) CL2018001716A1 (pt)
CO (1) CO2018007236A2 (pt)
DK (1) DK3394046T3 (pt)
ES (1) ES2913051T3 (pt)
IL (1) IL260212B (pt)
MX (1) MX388906B (pt)
PL (1) PL3394046T3 (pt)
PT (1) PT3394046T (pt)
RU (1) RU2730855C2 (pt)
WO (1) WO2017112950A1 (pt)
ZA (1) ZA201804229B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3394046T (pt) 2015-12-24 2022-04-05 Univ California Reguladores de cftr e seus métodos de uso
JP6938510B2 (ja) 2015-12-24 2021-09-22 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Cftr制御因子及びこの使用方法
CA3073718A1 (en) * 2017-08-24 2019-02-28 The Regents Of The University Of California Ocular pharmaceutical compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794209B (en) * 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
US4181724A (en) 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
FR2653430B1 (fr) 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6369057B1 (en) 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
AU5433594A (en) * 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU1917999A (en) 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
KR101352709B1 (ko) 2007-05-22 2014-01-16 아스테라스 세이야쿠 가부시키가이샤 1위 치환 테트라히드로이소퀴놀린 화합물
KR101637387B1 (ko) * 2008-03-05 2016-07-07 메르크 파텐트 게엠베하 인슐린 분비 자극제들로서의 퀴녹살리논 유도체들, 이들을 얻기 위한 방법들 및 당뇨병 치료를 위한 이들의 용도
CN102227430A (zh) 2008-10-23 2011-10-26 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
AU2013365827A1 (en) * 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds as CFTR inhibitors
WO2015168079A1 (en) * 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
PT3394046T (pt) 2015-12-24 2022-04-05 Univ California Reguladores de cftr e seus métodos de uso

Also Published As

Publication number Publication date
IL260212A (en) 2018-07-31
AU2016377785A1 (en) 2018-07-12
JP6938509B2 (ja) 2021-09-22
CL2018001716A1 (es) 2018-10-26
PL3394046T3 (pl) 2022-06-13
IL260212B (en) 2021-08-31
BR112018012934B1 (pt) 2023-11-07
NZ743725A (en) 2024-11-29
ES2913051T3 (es) 2022-05-31
JP2021185186A (ja) 2021-12-09
EP4071140C0 (en) 2024-07-03
JP7297828B2 (ja) 2023-06-26
ZA201804229B (en) 2021-10-27
EP3394046B1 (en) 2022-03-09
CN108699040A (zh) 2018-10-23
RU2018126957A (ru) 2020-01-27
KR102743295B1 (ko) 2024-12-17
JP2018538352A (ja) 2018-12-27
AU2016377785A2 (en) 2018-08-23
CO2018007236A2 (es) 2018-07-19
DK3394046T3 (da) 2022-04-04
US20210347742A1 (en) 2021-11-11
RU2730855C2 (ru) 2020-08-26
WO2017112950A1 (en) 2017-06-29
US20190031622A1 (en) 2019-01-31
KR20180101416A (ko) 2018-09-12
CA3009534A1 (en) 2017-06-29
EP4071140B1 (en) 2024-07-03
US12503447B2 (en) 2025-12-23
AU2016377785B2 (en) 2021-07-01
EP3394046A1 (en) 2018-10-31
BR112018012934A2 (pt) 2018-12-11
US11084795B2 (en) 2021-08-10
MX388906B (es) 2025-03-20
CN108699040B (zh) 2021-08-10
EP3394046A4 (en) 2019-06-19
RU2018126957A3 (pt) 2020-02-28
EP4071140A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
IL282048A (en) Oxysterols and methods of use thereof
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
PT3548033T (pt) Compostos e respectivos métodos de utilização
IL254039A0 (en) Anti-pvrig antibodies and methods of use
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
IL258768A (en) Glycan-interacting compounds and methods of use
CL2018000708A1 (es) Fitasas modificadas y métodos de uso
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PT3259253T (pt) Sulfonilureias e compostos relacionados e uso dos mesmos
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
PT3166937T (pt) Compostos antiproliferativos e métodos de uso dos mesmos
PT3218005T (pt) Compostos que interagem com glicano e métodos de uso
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
BR112016024034A2 (pt) ativadores de canal iônico e métodos de uso
BR112016020889A2 (pt) variantes de hppd e métodos de uso
CR20180296A (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
PL3411021T3 (pl) Nowe zastosowanie kombinacji sakubitrylu i walsartanu
ZA201804228B (en) Cftr regulators and methods of use thereof
PL3337506T3 (pl) Kombinacje i ich zastosowania
IL313083A (en) Terlipressin compositions and their methods of use
IL258023A (en) Systems and methods for trigger-based modification of privacy settings associated with posts
ZA201804230B (en) Cftr regulators and methods of use thereof